HLA-A2-RESTRICTED T-CELL EPITOPES OF THE RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN AS PEPTIDE-BASED VACCINES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 8, 2010
app pub date -
Dec 29, 2009
filing date -
Jan 4, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Respiratory syncytial virus (RSV) fusion protein-specific T-cell epitopes as peptide-based vaccines are disclosed. The isolated peptide contains a human HLA restricted CD8+ T-cell epitope that is specific to RSV F protein. The length of the peptide is no more than 9 or 10 amino acid residues. The peptide may be employed as an immunogen to stimulate cytotoxic T cells, indirectly activate helper T cells type 1, and cause release of cytokines from T cells.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully